MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
17.38
+0.78
+4.70%
Opening 10:42 05/22 EDT
OPEN
16.55
PREV CLOSE
16.60
HIGH
17.42
LOW
16.54
VOLUME
615.59K
TURNOVER
0
52 WEEK HIGH
30.07
52 WEEK LOW
6.46
MARKET CAP
2.69B
P/E (TTM)
78.82
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TGTX last week (0513-0517)?
Weekly Report · 2d ago
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics's short percent of float has fallen since its last report. The company has million shares sold short. Short interest is the number of shares that have been sold short but have not yet been covered. Short selling is when a trader sells shares of a company with the hope that the price will fall.
Benzinga · 05/14 14:30
Weekly Report: what happened at TGTX last week (0506-0510)?
Weekly Report · 05/13 11:59
Wall Street Breakfast: The Week Ahead
Wall Street Breakfast: The Week Ahead. Retail sales and consumer price index reports could move the needle on interest rate cut expectations. The earnings season will continue next week with results from Walmart and Home Depot. The artificial intelligence race could see some notable developments. Options trading volume is elevated on Barnes & Noble and AMC Entertainment.
Seeking Alpha · 05/12 11:04
Catalyst Watch: Retail heavyweights Walmart and Home Depot report, OpenAI vs. Google, and EV tariff drama
Microsoft-backed OpenAI expected to announce an AI search tool that could rival Google. Options trading volume is elevated on Barnes & Noble Education and AMC Entertainment. The most oversold stocks in the EV sector are expected to report on May 13 and 14. OPEC will release its monthly oil market report for May 10.
Seeking Alpha · 05/10 19:00
TG Therapeutics Under Pressure: Navigating the Perils of Government Contracts and Compliance Hurdles
TipRanks · 05/08 06:01
The title of the article could be "TG Therapeutics, Inc. Financial Report for Q1 2024".
Press release · 05/06 23:16
Weekly Report: what happened at TGTX last week (0429-0503)?
Weekly Report · 05/06 12:09
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.